MoonLake Immunotherapeutics

9.61-0.21 (-2.14%)

Oct 29, 4:00:00 PM EDT · NasdaqCM · MLTX · USD

Upcoming Earnings

Report date

≈ Nov 6, 2025 (in 7 days)

Key Stats

Market Cap

610.25M

P/E (TTM)

Basic EPS (TTM)

-2.79

Dividend Yield

Recent Filings

8-K

9/29/25Sep 29, 2025

10-Q

8/5/25Aug 5, 2025

8-K

8/5/25Aug 5, 2025

8-K

6/6/25Jun 6, 2025

8-K

5/12/25May 12, 2025

About

MoonLake Immunotherapeutics, a clinical stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

CEO

Dr. Jorge Santos da Silva Ph.D.

IPO

10/20/2020

Website

https://www.moonlaketx.com

Employees

100

Sector

Healthcare

Industry

Biotechnology